The 36-month beta value for VXRT is also noteworthy at 1.52. There are mixed opinions on the stock, with 4 analysts rating it as a “buy,” 0 rating it as “overweight,” 0 rating it as “hold,” and 0 rating it as “sell.”
The public float for VXRT is 225.15M, and at present, short sellers hold a 5.04% of that float. The average trading volume of VXRT on March 06, 2025 was 2.00M shares.
VXRT) stock’s latest price update
Vaxart Inc (NASDAQ: VXRT) has seen a rise in its stock price by 3.00 in relation to its previous close of 0.47. However, the company has experienced a -1.71% decline in its stock price over the last five trading sessions. globenewswire.com reported 2025-03-05 that Robust, antigen-specific responses in the nasal cavity following oral administration underscore the efficiency of Vaxart’s oral vaccine platform in generating mucosal antibody responses beyond the site of administration Robust, antigen-specific responses in the nasal cavity following oral administration underscore the efficiency of Vaxart’s oral vaccine platform in generating mucosal antibody responses beyond the site of administration
VXRT’s Market Performance
Vaxart Inc (VXRT) has seen a -1.71% fall in stock performance for the week, with a -32.21% decline in the past month and a -18.27% plunge in the past quarter. The volatility ratio for the week is 8.30%, and the volatility levels for the past 30 days are at 8.95% for VXRT. The simple moving average for the past 20 days is -21.74% for VXRT’s stock, with a -33.58% simple moving average for the past 200 days.
Analysts’ Opinion of VXRT
Many brokerage firms have already submitted their reports for VXRT stocks, with Oppenheimer repeating the rating for VXRT by listing it as a “Outperform.” The predicted price for VXRT in the upcoming period, according to Oppenheimer is $4 based on the research report published on August 15, 2024 of the previous year 2024.
Jefferies, on the other hand, stated in their research note that they expect to see VXRT reach a price target of $12, previously predicting the price at $13. The rating they have provided for VXRT stocks is “Buy” according to the report published on December 29th, 2021.
Cantor Fitzgerald gave a rating of “Overweight” to VXRT, setting the target price at $15 in the report published on November 02nd of the previous year.
VXRT Trading at -29.75% from the 50-Day Moving Average
After a stumble in the market that brought VXRT to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -65.67% of loss for the given period.
Volatility was left at 8.95%, however, over the last 30 days, the volatility rate increased by 8.30%, as shares sank -37.24% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -20.39% lower at present.
During the last 5 trading sessions, VXRT fell by -2.48%, which changed the moving average for the period of 200-days by -52.91% in comparison to the 20-day moving average, which settled at $0.6184. In addition, Vaxart Inc saw -26.88% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at VXRT starting from Watson W. Mark, who purchase 20,000 shares at the price of $0.68 back on Jun 18 ’24. After this action, Watson W. Mark now owns 78,125 shares of Vaxart Inc, valued at $13,578 using the latest closing price.
Stock Fundamentals for VXRT
Current profitability levels for the company are sitting at:
- -4.28 for the present operating margin
- -0.18 for the gross margin
The net margin for Vaxart Inc stands at -4.32. The total capital return value is set at -0.83. Equity return is now at value -103.37, with -53.13 for asset returns.
Based on Vaxart Inc (VXRT), the company’s capital structure generated 0.21 points at debt to capital in total, while cash flow to debt ratio is standing at -2.8. The debt to equity ratio resting at 0.27. The interest coverage ratio of the stock is -24.56.
Currently, EBITDA for the company is -72.13 million with net debt to EBITDA at 0.06. When we switch over and look at the enterprise to sales, we see a ratio of 6.33. The receivables turnover for the company is 4.56for trailing twelve months and the total asset turnover is 0.1. The liquidity ratio also appears to be rather interesting for investors as it stands at 0.83.
Conclusion
In summary, Vaxart Inc (VXRT) has had a bad performance as of late. Analysts have bullish opinions on the stock, with some viewing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
